Skip to main content
SpringerLink
Log in
Book cover

Handbook of Hepatitis C pp 49–60Cite as

Diagnosis

  • Chapter
  • First Online:

  • 1038 Accesses

Abstract

With the advent of highly active direct acting antivirals (DAAs) for the treatment of chronic hepatitis C, the goal of potential worldwide eradication of hepatitis C virus (HCV) infection seems achievable.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology. 2012;55:1652–1661.

    Google Scholar 

  2. Meffre C, Le Strat Y, Delarocque-Astagneau E, et al. Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol. 2010;82:546–555.

    Google Scholar 

  3. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic epatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61:1–32.

    Google Scholar 

  4. Grebely J, Bilodeau M, Feld, JJ, et al. The second Canadian symposium on hepatitis C virus: a call to action. Can J Gastroenterol. 2013;27:627–632.

    Google Scholar 

  5. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.

    Google Scholar 

  6. Moyer VA, US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349–357.

    Google Scholar 

  7. Coyle J, Brousseau G, George E, Eckel S, Macomber K. Evaluation of CDC’s Hepatitis C Birth-ohort Screening Recommendation Using Medical Claims Data. The Council of State and Territorial Epidemiologists (CSTE) Annual Conference. June 14–18, 2015; Boston, US.

    Google Scholar 

  8. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236.

    Google Scholar 

  9. Centers for Disease Control and Prevention (CDC). Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62:362–365.

    Google Scholar 

  10. Alter HJ, Aragon T, AuBuchon JP, et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47:1–39.

    Google Scholar 

  11. Alter MJ, Kuhnert WL, Finelli L. Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003;52:1–13.

    Google Scholar 

  12. Khuroo MS, Khuroo NS, Khuroo MS. Diagnostic accuracy of point-of-care tests for hepatitis C virus infection: a systematic review and meta-analysis. PLoS One. 2015;10:e0121450.

    Google Scholar 

  13. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of epatitis C virus genotypes. Hepatology. 2005;42:962–973.

    Google Scholar 

  14. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–327.

    Google Scholar 

  15. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403–2412.

    Google Scholar 

  16. Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay or hepatitis C virus genotyping. J Clin Microbiol. 1996;34:2259–2266.

    Google Scholar 

  17. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One. 2009;4:e8209.

    Google Scholar 

  18. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.

    Google Scholar 

  19. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293.

    Google Scholar 

  20. King LY, Canasto-Chibuque C, Johnson KB. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut.2015;64:1296–1302.

    Google Scholar 

  21. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457.

    Google Scholar 

  22. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477–481.

    Google Scholar 

  23. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165–173.

    Google Scholar 

  24. Ble M, Procopet B, Miquel R, Hernandez-Gea V, Garcia-Pagan. Transjugular liver biopsy. Clin Liver Dis. 2014;18:767–778.

    Google Scholar 

  25. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293–1302.

    Google Scholar 

  26. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.

    Google Scholar 

  27. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB‐4: an inexpensive and accurate marker of fibrosis in CV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32–36.

    Google Scholar 

  28. Forns X, Ampurdanes S, Llovet JM, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–992.

    Google Scholar 

  29. Lok AS, Ghany MG, Goodman ZD, et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT‐C cohort. Hepatology. 2005;42:282–292.

    Google Scholar 

  30. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–1075.

    Google Scholar 

  31. Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–835.

    Google Scholar 

  32. Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.

    Google Scholar 

  33. Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic adiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2011;106:2112–2120.

    Google Scholar 

  34. Boursier J, de Ledinghen V, Zarski JP. Comparison of eight diagnostic algorithms for liver fibrosis in epatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55:58–67.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, USA

    Nicolas Goossens

  2. Department of Clinical Pathology, Faculty of Medicine, Geneva University Hospitals, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Geneva University Hospitals, Geneva, Geneve, Switzerland

    Francesco Negro

Authors
  1. Nicolas Goossens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Clément
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francesco Negro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Nicolas Goossens

  2. University Hospitals and Faculty of Medi, Clinical Pathology, Geneva, Geneve, Switzerland

    Sophie Clément

  3. Division of Gastroenterology and Hepatol, Geneva University Hospital, Geneva 14, Geneve, Switzerland

    Francesco Negro

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Goossens, N., Clément, S., Negro, F. (2016). Diagnosis. In: Goossens, N., Clément, S., Negro, F. (eds) Handbook of Hepatitis C . Adis, Cham. https://doi.org/10.1007/978-3-319-28053-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-28053-0_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-28051-6

  • Online ISBN: 978-3-319-28053-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation